Pharmacia's new inhaled anesthetic Suprane R (desflurane) should be available in most European countries by early 1995, according to Peter Benson, president of the company's hospital care division, speaking at an international symposium on anesthesia in Barcelona, Spain.
The product was launched in the UK and Sweden last year, and in Finland earlier in 1994. It was recently approved by the European Union's Committee on Proprietary Medicinal Products, opening the way for its approval elsewhere in Europe.
Desflurane reportedly has a lower blood and tissue solubility than other potent inhaled anesthetics. As a result, the agent is taken up and eliminated more rapidly, permitting a precise control of the depth and duration of anesthesia. Several studies presented at the Barcelona meeting indicated that the recovery time from anesthesia with desflurane is two-to-four times faster than it is with the widely-used inhalant isoflurane.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze